UA78484C2 - Method of radioactive marking of cd 20 antibody - Google Patents

Method of radioactive marking of cd 20 antibody Download PDF

Info

Publication number: UA78484C2
Authority: UA; Ukraine
Prior art keywords: cells; antibody; labeled; antibodies; dtpk
Prior art date: 1999-03-01

Application number

UA2001096636A

Other languages

English (en)

Ukrainian (uk)

Inventor

John E Leonard

Original Assignee

Idek Pharmaceuticals Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-03-01

Filing date

2000-02-29

Publication date

2007-04-10

2000-02-29 Application filed by Idek Pharmaceuticals Corp filed Critical Idek Pharmaceuticals Corp

2007-04-10 Publication of UA78484C2 publication Critical patent/UA78484C2/uk

Links

238000000034 method Methods 0.000 title abstract description 130
230000002285 radioactive effect Effects 0.000 title abstract description 44
230000000694 effects Effects 0.000 abstract description 81
238000000746 purification Methods 0.000 abstract description 21
VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 abstract description 19
229910052727 yttrium Inorganic materials 0.000 abstract description 18
238000002156 mixing Methods 0.000 abstract description 10
239000000126 substance Substances 0.000 abstract description 4
VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 abstract description 3
210000004027 cell Anatomy 0.000 description 316
238000004458 analytical method Methods 0.000 description 123
230000027455 binding Effects 0.000 description 117
238000012360 testing method Methods 0.000 description 83
241000699670 Mus sp. Species 0.000 description 76
210000003719 b-lymphocyte Anatomy 0.000 description 75
210000000988 bone and bone Anatomy 0.000 description 71
239000000872 buffer Substances 0.000 description 68
239000000427 antigen Substances 0.000 description 66
108091007433 antigens Proteins 0.000 description 65
102000036639 antigens Human genes 0.000 description 65
238000006243 chemical reaction Methods 0.000 description 62
210000001519 tissue Anatomy 0.000 description 58
238000002372 labelling Methods 0.000 description 57
210000002966 serum Anatomy 0.000 description 54
239000000243 solution Substances 0.000 description 53
238000002360 preparation method Methods 0.000 description 52
239000003153 chemical reaction reagent Substances 0.000 description 49
108090000623 proteins and genes Proteins 0.000 description 47
238000000163 radioactive labelling Methods 0.000 description 46
241001465754 Metazoa Species 0.000 description 42
238000011534 incubation Methods 0.000 description 42
206010028980 Neoplasm Diseases 0.000 description 41
210000004369 blood Anatomy 0.000 description 41
239000008280 blood Substances 0.000 description 41
239000000499 gel Substances 0.000 description 38
210000003734 kidney Anatomy 0.000 description 38
210000004072 lung Anatomy 0.000 description 38
239000000203 mixture Substances 0.000 description 38
235000018102 proteins Nutrition 0.000 description 38
102000004169 proteins and genes Human genes 0.000 description 38
210000003205 muscle Anatomy 0.000 description 36
210000000056 organ Anatomy 0.000 description 36
210000004185 liver Anatomy 0.000 description 34
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 33
210000000952 spleen Anatomy 0.000 description 32
210000004907 gland Anatomy 0.000 description 29
230000005855 radiation Effects 0.000 description 27
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 26
238000002474 experimental method Methods 0.000 description 26
239000000523 sample Substances 0.000 description 26
239000001632 sodium acetate Substances 0.000 description 26
235000017281 sodium acetate Nutrition 0.000 description 26
210000004698 lymphocyte Anatomy 0.000 description 25
239000007924 injection Substances 0.000 description 24
238000002347 injection Methods 0.000 description 24
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 23
238000009826 distribution Methods 0.000 description 23
230000001965 increasing effect Effects 0.000 description 23
229910052751 metal Inorganic materials 0.000 description 23
239000002184 metal Substances 0.000 description 23
210000001672 ovary Anatomy 0.000 description 23
230000001225 therapeutic effect Effects 0.000 description 23
108091006905 Human Serum Albumin Proteins 0.000 description 22
102000008100 Human Serum Albumin Human genes 0.000 description 22
241000699666 Mus <mouse, genus> Species 0.000 description 22
210000001185 bone marrow Anatomy 0.000 description 22
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 21
-1 NORSO)H" Chemical compound 0.000 description 21
210000002216 heart Anatomy 0.000 description 21
210000001685 thyroid gland Anatomy 0.000 description 21
239000004743 Polypropylene Substances 0.000 description 20
239000006228 supernatant Substances 0.000 description 20
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 19
238000005119 centrifugation Methods 0.000 description 19
230000008569 process Effects 0.000 description 19
210000002784 stomach Anatomy 0.000 description 18
210000001550 testis Anatomy 0.000 description 18
UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 18
230000021615 conjugation Effects 0.000 description 17
238000010790 dilution Methods 0.000 description 17
239000012895 dilution Substances 0.000 description 17
229920001155 polypropylene Polymers 0.000 description 17
230000001186 cumulative effect Effects 0.000 description 16
210000004556 brain Anatomy 0.000 description 15
239000013522 chelant Substances 0.000 description 15
238000010348 incorporation Methods 0.000 description 15
239000000463 material Substances 0.000 description 15
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 14
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 14
238000001962 electrophoresis Methods 0.000 description 14
230000009257 reactivity Effects 0.000 description 14
238000011282 treatment Methods 0.000 description 14
210000001744 T-lymphocyte Anatomy 0.000 description 13
229910052738 indium Inorganic materials 0.000 description 13
APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 13
SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 13
238000003608 radiolysis reaction Methods 0.000 description 13
GUJDUXMBBAOBHN-UHFFFAOYSA-N 6-(dimethylamino)-n-(2h-tetrazol-5-yl)pyrazine-2-carboxamide Chemical compound CN(C)C1=CN=CC(C(=O)NC2=NNN=N2)=N1 GUJDUXMBBAOBHN-UHFFFAOYSA-N 0.000 description 12
210000004100 adrenal gland Anatomy 0.000 description 12
230000007423 decrease Effects 0.000 description 12
239000013024 dilution buffer Substances 0.000 description 12
239000004744 fabric Substances 0.000 description 12
230000014759 maintenance of location Effects 0.000 description 12
241000283707 Capra Species 0.000 description 11
241000282553 Macaca Species 0.000 description 11
241001529936 Murinae Species 0.000 description 11
239000003814 drug Substances 0.000 description 11
210000003608 fece Anatomy 0.000 description 11
210000001035 gastrointestinal tract Anatomy 0.000 description 11
238000005259 measurement Methods 0.000 description 11
239000000047 product Substances 0.000 description 11
230000002829 reductive effect Effects 0.000 description 11
241000282693 Cercopithecidae Species 0.000 description 10
239000004471 Glycine Substances 0.000 description 10
206010025323 Lymphomas Diseases 0.000 description 10
238000000211 autoradiogram Methods 0.000 description 10
229940079593 drug Drugs 0.000 description 10
239000011521 glass Substances 0.000 description 10
210000005260 human cell Anatomy 0.000 description 10
238000004519 manufacturing process Methods 0.000 description 10
210000004291 uterus Anatomy 0.000 description 10
AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 9
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
208000003950 B-cell lymphoma Diseases 0.000 description 9
230000001919 adrenal effect Effects 0.000 description 9
238000000376 autoradiography Methods 0.000 description 9
210000000845 cartilage Anatomy 0.000 description 9
238000011161 development Methods 0.000 description 9
239000010985 leather Substances 0.000 description 9
210000000496 pancreas Anatomy 0.000 description 9
238000000159 protein binding assay Methods 0.000 description 9
230000004044 response Effects 0.000 description 9
102000009027 Albumins Human genes 0.000 description 8
108010088751 Albumins Proteins 0.000 description 8
230000001413 cellular effect Effects 0.000 description 8
238000004587 chromatography analysis Methods 0.000 description 8
230000006378 damage Effects 0.000 description 8
239000012510 hollow fiber Substances 0.000 description 8
210000004408 hybridoma Anatomy 0.000 description 8
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
239000002253 acid Substances 0.000 description 7
210000000577 adipose tissue Anatomy 0.000 description 7
238000013459 approach Methods 0.000 description 7
230000008901 benefit Effects 0.000 description 7
230000001588 bifunctional effect Effects 0.000 description 7
238000004364 calculation method Methods 0.000 description 7
230000003247 decreasing effect Effects 0.000 description 7
230000008034 disappearance Effects 0.000 description 7
238000004108 freeze drying Methods 0.000 description 7
230000036512 infertility Effects 0.000 description 7
230000004807 localization Effects 0.000 description 7
239000004033 plastic Substances 0.000 description 7
229920003023 plastic Polymers 0.000 description 7
238000011160 research Methods 0.000 description 7
210000004881 tumor cell Anatomy 0.000 description 7
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
108020004414 DNA Proteins 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
241000282838 Lama Species 0.000 description 6
KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 6
102000007562 Serum Albumin Human genes 0.000 description 6
108010071390 Serum Albumin Proteins 0.000 description 6
231100000987 absorbed dose Toxicity 0.000 description 6
238000009825 accumulation Methods 0.000 description 6
238000003556 assay Methods 0.000 description 6
230000002860 competitive effect Effects 0.000 description 6
239000012467 final product Substances 0.000 description 6
239000006166 lysate Substances 0.000 description 6
238000002844 melting Methods 0.000 description 6
230000008018 melting Effects 0.000 description 6
239000002245 particle Substances 0.000 description 6
238000005192 partition Methods 0.000 description 6
235000021251 pulses Nutrition 0.000 description 6
239000011541 reaction mixture Substances 0.000 description 6
229910052707 ruthenium Inorganic materials 0.000 description 6
210000000813 small intestine Anatomy 0.000 description 6
239000011734 sodium Substances 0.000 description 6
229910052708 sodium Inorganic materials 0.000 description 6
239000008223 sterile water Substances 0.000 description 6
238000004809 thin layer chromatography Methods 0.000 description 6
230000035899 viability Effects 0.000 description 6
238000005406 washing Methods 0.000 description 6
ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 5
241000283690 Bos taurus Species 0.000 description 5
108091003079 Bovine Serum Albumin Proteins 0.000 description 5
235000019687 Lamb Nutrition 0.000 description 5
238000010521 absorption reaction Methods 0.000 description 5
210000005068 bladder tissue Anatomy 0.000 description 5
239000012888 bovine serum Substances 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
230000009137 competitive binding Effects 0.000 description 5
230000009089 cytolysis Effects 0.000 description 5
238000004980 dosimetry Methods 0.000 description 5
238000011156 evaluation Methods 0.000 description 5
239000002609 medium Substances 0.000 description 5
229940126619 mouse monoclonal antibody Drugs 0.000 description 5
238000000763 radioactive isotope labeling Methods 0.000 description 5
230000003537 radioprotector Effects 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
231100000027 toxicology Toxicity 0.000 description 5
210000000689 upper leg Anatomy 0.000 description 5
210000002700 urine Anatomy 0.000 description 5
238000005303 weighing Methods 0.000 description 5
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
206010049647 Adrenal cyst Diseases 0.000 description 4
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
235000017274 Diospyros sandwicensis Nutrition 0.000 description 4
229940110339 Long-acting muscarinic antagonist Drugs 0.000 description 4
229930195725 Mannitol Natural products 0.000 description 4
239000011324 bead Substances 0.000 description 4
229940098773 bovine serum albumin Drugs 0.000 description 4
239000006285 cell suspension Substances 0.000 description 4
238000012512 characterization method Methods 0.000 description 4
230000034994 death Effects 0.000 description 4
230000004069 differentiation Effects 0.000 description 4
230000002550 fecal effect Effects 0.000 description 4
230000004927 fusion Effects 0.000 description 4
230000012010 growth Effects 0.000 description 4
238000003384 imaging method Methods 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
229910052740 iodine Inorganic materials 0.000 description 4
239000011630 iodine Substances 0.000 description 4
210000002429 large intestine Anatomy 0.000 description 4
210000001165 lymph node Anatomy 0.000 description 4
239000000594 mannitol Substances 0.000 description 4
235000010355 mannitol Nutrition 0.000 description 4
239000003550 marker Substances 0.000 description 4
150000002739 metals Chemical class 0.000 description 4
210000003739 neck Anatomy 0.000 description 4
230000009871 nonspecific binding Effects 0.000 description 4
210000005259 peripheral blood Anatomy 0.000 description 4
239000011886 peripheral blood Substances 0.000 description 4
238000012545 processing Methods 0.000 description 4
230000035755 proliferation Effects 0.000 description 4
239000002510 pyrogen Substances 0.000 description 4
239000000725 suspension Substances 0.000 description 4
OBOSXEWFRARQPU-UHFFFAOYSA-N 2-n,2-n-dimethylpyridine-2,5-diamine Chemical compound CN(C)C1=CC=C(N)C=N1 OBOSXEWFRARQPU-UHFFFAOYSA-N 0.000 description 3
102000014914 Carrier Proteins Human genes 0.000 description 3
108010078791 Carrier Proteins Proteins 0.000 description 3
229920000742 Cotton Polymers 0.000 description 3
101100536354 Drosophila melanogaster tant gene Proteins 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
206010035226 Plasma cell myeloma Diseases 0.000 description 3
241000288906 Primates Species 0.000 description 3
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 3
206010052428 Wound Diseases 0.000 description 3
208000027418 Wounds and injury Diseases 0.000 description 3
238000002835 absorbance Methods 0.000 description 3
239000002671 adjuvant Substances 0.000 description 3
239000012491 analyte Substances 0.000 description 3
208000016063 arterial thoracic outlet syndrome Diseases 0.000 description 3
229940072107 ascorbate Drugs 0.000 description 3
235000010323 ascorbic acid Nutrition 0.000 description 3
239000011668 ascorbic acid Substances 0.000 description 3
238000003149 assay kit Methods 0.000 description 3
150000001540 azides Chemical class 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
230000008859 change Effects 0.000 description 3
210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
238000004140 cleaning Methods 0.000 description 3
238000004891 communication Methods 0.000 description 3
239000012141 concentrate Substances 0.000 description 3
238000011109 contamination Methods 0.000 description 3
238000004163 cytometry Methods 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
230000007717 exclusion Effects 0.000 description 3
238000003818 flash chromatography Methods 0.000 description 3
238000000684 flow cytometry Methods 0.000 description 3
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
235000013305 food Nutrition 0.000 description 3
230000006870 function Effects 0.000 description 3
101150077246 gas5 gene Proteins 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
239000011544 gradient gel Substances 0.000 description 3
229910001385 heavy metal Inorganic materials 0.000 description 3
230000001900 immune effect Effects 0.000 description 3
230000028993 immune response Effects 0.000 description 3
210000000987 immune system Anatomy 0.000 description 3
229940127121 immunoconjugate Drugs 0.000 description 3
230000006698 induction Effects 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
230000003993 interaction Effects 0.000 description 3
210000000936 intestine Anatomy 0.000 description 3
238000010253 intravenous injection Methods 0.000 description 3
230000000155 isotopic effect Effects 0.000 description 3
238000004811 liquid chromatography Methods 0.000 description 3
230000003211 malignant effect Effects 0.000 description 3
244000005700 microbiome Species 0.000 description 3
201000000050 myeloid neoplasm Diseases 0.000 description 3
230000001613 neoplastic effect Effects 0.000 description 3
230000002093 peripheral effect Effects 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
238000003127 radioimmunoassay Methods 0.000 description 3
238000011084 recovery Methods 0.000 description 3
230000000405 serological effect Effects 0.000 description 3
210000003491 skin Anatomy 0.000 description 3
239000002904 solvent Substances 0.000 description 3
239000000758 substrate Substances 0.000 description 3
238000011285 therapeutic regimen Methods 0.000 description 3
210000001541 thymus gland Anatomy 0.000 description 3
238000002562 urinalysis Methods 0.000 description 3
210000003462 vein Anatomy 0.000 description 3
238000012795 verification Methods 0.000 description 3
DFUSDJMZWQVQSF-XLGIIRLISA-N (2r)-2-methyl-2-[(4r,8r)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-ol Chemical class OC1=CC=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 DFUSDJMZWQVQSF-XLGIIRLISA-N 0.000 description 2
PFFIDZXUXFLSSR-UHFFFAOYSA-N 1-methyl-N-[2-(4-methylpentan-2-yl)-3-thienyl]-3-(trifluoromethyl)pyrazole-4-carboxamide Chemical compound S1C=CC(NC(=O)C=2C(=NN(C)C=2)C(F)(F)F)=C1C(C)CC(C)C PFFIDZXUXFLSSR-UHFFFAOYSA-N 0.000 description 2
WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
DGZSVBBLLGZHSF-UHFFFAOYSA-N 4,4-diethylpiperidine Chemical compound CCC1(CC)CCNCC1 DGZSVBBLLGZHSF-UHFFFAOYSA-N 0.000 description 2
235000002198 Annona diversifolia Nutrition 0.000 description 2
206010003445 Ascites Diseases 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
208000037914 B-cell disorder Diseases 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
240000006240 Linum usitatissimum Species 0.000 description 2
235000004431 Linum usitatissimum Nutrition 0.000 description 2
241001123862 Mico Species 0.000 description 2
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
241000468053 Obodhiang virus Species 0.000 description 2
VXPUTYRUGAZODI-UHFFFAOYSA-B P(=O)([O-])([O-])[O-].[Re+4].P(=O)([O-])([O-])[O-].P(=O)([O-])([O-])[O-].P(=O)([O-])([O-])[O-].[Re+4].[Re+4] Chemical compound P(=O)([O-])([O-])[O-].[Re+4].P(=O)([O-])([O-])[O-].P(=O)([O-])([O-])[O-].P(=O)([O-])([O-])[O-].[Re+4].[Re+4] VXPUTYRUGAZODI-UHFFFAOYSA-B 0.000 description 2
244000046052 Phaseolus vulgaris Species 0.000 description 2
235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
229920002684 Sepharose Polymers 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
244000269722 Thea sinensis Species 0.000 description 2
241000251539 Vertebrata <Metazoa> Species 0.000 description 2
230000009471 action Effects 0.000 description 2
238000001994 activation Methods 0.000 description 2
238000001042 affinity chromatography Methods 0.000 description 2
238000000149 argon plasma sintering Methods 0.000 description 2
239000003855 balanced salt solution Substances 0.000 description 2
229910021538 borax Inorganic materials 0.000 description 2
244000309464 bull Species 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
229920001429 chelating resin Polymers 0.000 description 2
230000009920 chelation Effects 0.000 description 2
239000000460 chlorine Substances 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
210000001072 colon Anatomy 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
230000001268 conjugating effect Effects 0.000 description 2
239000002274 desiccant Substances 0.000 description 2
238000001514 detection method Methods 0.000 description 2
238000011026 diafiltration Methods 0.000 description 2
238000000502 dialysis Methods 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
239000012636 effector Substances 0.000 description 2
230000029142 excretion Effects 0.000 description 2
238000013213 extrapolation Methods 0.000 description 2
235000019197 fats Nutrition 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000000834 fixative Substances 0.000 description 2
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
238000005242 forging Methods 0.000 description 2
238000009472 formulation Methods 0.000 description 2
230000003394 haemopoietic effect Effects 0.000 description 2
238000001114 immunoprecipitation Methods 0.000 description 2
230000001976 improved effect Effects 0.000 description 2
LBGSDOMRVQPKJM-UHFFFAOYSA-N indium yttrium Chemical compound [Y][In] LBGSDOMRVQPKJM-UHFFFAOYSA-N 0.000 description 2
210000004969 inflammatory cell Anatomy 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
230000005865 ionizing radiation Effects 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
239000003446 ligand Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
210000003563 lymphoid tissue Anatomy 0.000 description 2
FRSRGACXHCLBTC-UHFFFAOYSA-N methyl n-(3,5-dichlorophenyl)carbamate Chemical compound COC(=O)NC1=CC(Cl)=CC(Cl)=C1 FRSRGACXHCLBTC-UHFFFAOYSA-N 0.000 description 2
210000000663 muscle cell Anatomy 0.000 description 2
238000009206 nuclear medicine Methods 0.000 description 2
238000005457 optimization Methods 0.000 description 2
229920002866 paraformaldehyde Polymers 0.000 description 2
239000008188 pellet Substances 0.000 description 2
229960003330 pentetic acid Drugs 0.000 description 2
239000013641 positive control Substances 0.000 description 2
239000000843 powder Substances 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
238000004445 quantitative analysis Methods 0.000 description 2
239000000700 radioactive tracer Substances 0.000 description 2
238000011363 radioimmunotherapy Methods 0.000 description 2
239000011535 reaction buffer Substances 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000029219 regulation of pH Effects 0.000 description 2
YAYGSLOSTXKUBW-UHFFFAOYSA-N ruthenium(2+) Chemical compound [Ru+2] YAYGSLOSTXKUBW-UHFFFAOYSA-N 0.000 description 2
210000003296 saliva Anatomy 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
239000001509 sodium citrate Substances 0.000 description 2
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
235000010339 sodium tetraborate Nutrition 0.000 description 2
239000004334 sorbic acid Substances 0.000 description 2
241000894007 species Species 0.000 description 2
210000000278 spinal cord Anatomy 0.000 description 2
210000004988 splenocyte Anatomy 0.000 description 2
230000006641 stabilisation Effects 0.000 description 2
238000011105 stabilization Methods 0.000 description 2
238000003860 storage Methods 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
210000004243 sweat Anatomy 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
239000003053 toxin Substances 0.000 description 2
231100000765 toxin Toxicity 0.000 description 2
108700012359 toxins Proteins 0.000 description 2
238000012546 transfer Methods 0.000 description 2
230000032258 transport Effects 0.000 description 2
BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 2
238000009423 ventilation Methods 0.000 description 2
238000012800 visualization Methods 0.000 description 2
239000008215 water for injection Substances 0.000 description 2
235000014101 wine Nutrition 0.000 description 2
TYKASZBHFXBROF-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-(2,5-dioxopyrrol-1-yl)acetate Chemical compound O=C1CCC(=O)N1OC(=O)CN1C(=O)C=CC1=O TYKASZBHFXBROF-UHFFFAOYSA-N 0.000 description 1
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
GYNXTHOOAGYMOK-UHFFFAOYSA-N 2-hydroxybutanediamide Chemical compound NC(=O)CC(O)C(N)=O GYNXTHOOAGYMOK-UHFFFAOYSA-N 0.000 description 1
102000007469 Actins Human genes 0.000 description 1
108010085238 Actins Proteins 0.000 description 1
241001552669 Adonis annua Species 0.000 description 1
241000282979 Alces alces Species 0.000 description 1
235000006578 Althaea Nutrition 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
239000005695 Ammonium acetate Substances 0.000 description 1
208000000044 Amnesia Diseases 0.000 description 1
235000019737 Animal fat Nutrition 0.000 description 1
241000256844 Apis mellifera Species 0.000 description 1
208000035404 Autolysis Diseases 0.000 description 1
102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
241000954177 Bangana ariza Species 0.000 description 1
ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical compound N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
230000005461 Bremsstrahlung Effects 0.000 description 1
101100074829 Caenorhabditis elegans lin-13 gene Proteins 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
235000002566 Capsicum Nutrition 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
206010057248 Cell death Diseases 0.000 description 1
241000282994 Cervidae Species 0.000 description 1
241000040710 Chela Species 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
244000241257 Cucumis melo Species 0.000 description 1
235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
244000301850 Cupressus sempervirens Species 0.000 description 1
244000019459 Cynara cardunculus Species 0.000 description 1
235000019106 Cynara scolymus Nutrition 0.000 description 1
101100291267 Drosophila melanogaster Miga gene Proteins 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
239000004386 Erythritol Substances 0.000 description 1
UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
240000002989 Euphorbia neriifolia Species 0.000 description 1
229940123457 Free radical scavenger Drugs 0.000 description 1
241000755093 Gaidropsarus vulgaris Species 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
235000010469 Glycine max Nutrition 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
241000288140 Gruiformes Species 0.000 description 1
244000130592 Hibiscus syriacus Species 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
208000021519 Hodgkin lymphoma Diseases 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
241000282418 Hominidae Species 0.000 description 1
101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
241000257303 Hymenoptera Species 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
241000283111 Macroderes minutus Species 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
241000699673 Mesocricetus auratus Species 0.000 description 1
101100498160 Mus musculus Dach1 gene Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
101100491259 Oryza sativa subsp. japonica AP2-2 gene Proteins 0.000 description 1
101710160107 Outer membrane protein A Proteins 0.000 description 1
102100026459 POU domain, class 3, transcription factor 2 Human genes 0.000 description 1
101710133394 POU domain, class 3, transcription factor 2 Proteins 0.000 description 1
241001602688 Pama Species 0.000 description 1
235000008753 Papaver somniferum Nutrition 0.000 description 1
241000218180 Papaveraceae Species 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
239000006002 Pepper Substances 0.000 description 1
206010057249 Phagocytosis Diseases 0.000 description 1
108010004729 Phycoerythrin Proteins 0.000 description 1
235000016761 Piper aduncum Nutrition 0.000 description 1
235000017804 Piper guineense Nutrition 0.000 description 1
244000203593 Piper nigrum Species 0.000 description 1
235000008184 Piper nigrum Nutrition 0.000 description 1
241000514450 Podocarpus latifolius Species 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
208000037062 Polyps Diseases 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
108010071690 Prealbumin Proteins 0.000 description 1
102000007584 Prealbumin Human genes 0.000 description 1
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
102000029797 Prion Human genes 0.000 description 1
108091000054 Prion Proteins 0.000 description 1
241000219492 Quercus Species 0.000 description 1
241000700159 Rattus Species 0.000 description 1
208000037656 Respiratory Sounds Diseases 0.000 description 1
241000612182 Rexea solandri Species 0.000 description 1
241000220317 Rosa Species 0.000 description 1
206010040844 Skin exfoliation Diseases 0.000 description 1
206010040860 Skin haemorrhages Diseases 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
108091008874 T cell receptors Proteins 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
241001441723 Takifugu Species 0.000 description 1
241001424341 Tara spinosa Species 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
GIEAQDPIWWODTH-UHFFFAOYSA-N [Na].[Na].[Na].[Ca] Chemical compound [Na].[Na].[Na].[Ca] GIEAQDPIWWODTH-UHFFFAOYSA-N 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
235000019257 ammonium acetate Nutrition 0.000 description 1
229940043376 ammonium acetate Drugs 0.000 description 1
239000003708 ampul Substances 0.000 description 1
230000031016 anaphase Effects 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
238000000137 annealing Methods 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000002421 anti-septic effect Effects 0.000 description 1
238000011091 antibody purification Methods 0.000 description 1
230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
235000016520 artichoke thistle Nutrition 0.000 description 1
230000001174 ascending effect Effects 0.000 description 1
235000010385 ascorbyl palmitate Nutrition 0.000 description 1
238000011888 autopsy Methods 0.000 description 1
239000012148 binding buffer Substances 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
238000010322 bone marrow transplantation Methods 0.000 description 1
229910052796 boron Inorganic materials 0.000 description 1
239000005388 borosilicate glass Substances 0.000 description 1
210000004958 brain cell Anatomy 0.000 description 1
229920005549 butyl rubber Polymers 0.000 description 1
229910002091 carbon monoxide Inorganic materials 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
210000005056 cell body Anatomy 0.000 description 1
108091092356 cellular DNA Proteins 0.000 description 1
230000007969 cellular immunity Effects 0.000 description 1
230000007541 cellular toxicity Effects 0.000 description 1
235000013351 cheese Nutrition 0.000 description 1
150000004697 chelate complex Chemical class 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
230000007012 clinical effect Effects 0.000 description 1
229910052681 coesite Inorganic materials 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
238000012875 competitive assay Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000007799 cork Substances 0.000 description 1
230000001054 cortical effect Effects 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
238000005336 cracking Methods 0.000 description 1
229910052906 cristobalite Inorganic materials 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
230000001955 cumulated effect Effects 0.000 description 1
XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
229960002433 cysteine Drugs 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
238000010217 densitometric analysis Methods 0.000 description 1
230000008021 deposition Effects 0.000 description 1
239000003599 detergent Substances 0.000 description 1
VBXWCGWXDOBUQZ-UHFFFAOYSA-K diacetyloxyindiganyl acetate Chemical compound [In+3].CC([O-])=O.CC([O-])=O.CC([O-])=O VBXWCGWXDOBUQZ-UHFFFAOYSA-K 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000002059 diagnostic imaging Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000018459 dissociative disease Diseases 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
AOJJSUZBOXZQNB-TZSSRYMLSA-N doxorubicine Natural products O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
238000005868 electrolysis reaction Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical compound C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 1
235000019414 erythritol Nutrition 0.000 description 1
UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
229940009714 erythritol Drugs 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
238000002270 exclusion chromatography Methods 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
239000000835 fiber Substances 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
238000011049 filling Methods 0.000 description 1
235000004426 flaxseed Nutrition 0.000 description 1
239000012530 fluid Substances 0.000 description 1
235000012631 food intake Nutrition 0.000 description 1
WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Substances O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
239000012634 fragment Substances 0.000 description 1
235000021022 fresh fruits Nutrition 0.000 description 1
238000003958 fumigation Methods 0.000 description 1
238000002825 functional assay Methods 0.000 description 1
239000007789 gas Substances 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
210000003736 gastrointestinal content Anatomy 0.000 description 1
238000005227 gel permeation chromatography Methods 0.000 description 1
238000001879 gelation Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
229960005219 gentisic acid Drugs 0.000 description 1
230000002518 glial effect Effects 0.000 description 1
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
210000004209 hair Anatomy 0.000 description 1
LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 1
230000036541 health Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
230000004727 humoral immunity Effects 0.000 description 1
210000004754 hybrid cell Anatomy 0.000 description 1
SRSMHCPRTXUJJM-KAHIACEGSA-N hydropyrene Chemical compound C[C@@H]1CC[C@@H]2[C@@H]3[C@H]1CC[C@]1(C)CCC[C@](C)(CC2=C)[C@@H]31 SRSMHCPRTXUJJM-KAHIACEGSA-N 0.000 description 1
210000003405 ileum Anatomy 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
230000036046 immunoreaction Effects 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
238000009434 installation Methods 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
230000002262 irrigation Effects 0.000 description 1
238000003973 irrigation Methods 0.000 description 1
210000002239 ischium bone Anatomy 0.000 description 1
238000001948 isotopic labelling Methods 0.000 description 1
238000002386 leaching Methods 0.000 description 1
210000002414 leg Anatomy 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
231100000863 loss of memory Toxicity 0.000 description 1
238000004020 luminiscence type Methods 0.000 description 1
208000003747 lymphoid leukemia Diseases 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
210000005075 mammary gland Anatomy 0.000 description 1
238000009607 mammography Methods 0.000 description 1
QZIQJVCYUQZDIR-UHFFFAOYSA-N mechlorethamine hydrochloride Chemical compound Cl.ClCCN(C)CCCl QZIQJVCYUQZDIR-UHFFFAOYSA-N 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
HNJJXZKZRAWDPF-UHFFFAOYSA-N methapyrilene Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CS1 HNJJXZKZRAWDPF-UHFFFAOYSA-N 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
239000013642 negative control Substances 0.000 description 1
235000001968 nicotinic acid Nutrition 0.000 description 1
229960003512 nicotinic acid Drugs 0.000 description 1
239000011664 nicotinic acid Substances 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
238000000399 optical microscopy Methods 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
238000010979 pH adjustment Methods 0.000 description 1
210000002741 palatine tonsil Anatomy 0.000 description 1
230000000149 penetrating effect Effects 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
210000004976 peripheral blood cell Anatomy 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
102000013415 peroxidase activity proteins Human genes 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
230000008782 phagocytosis Effects 0.000 description 1
150000002989 phenols Chemical class 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920006324 polyoxymethylene Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
230000001376 precipitating effect Effects 0.000 description 1
238000012910 preclinical development Methods 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
108010015658 protodyne Proteins 0.000 description 1
210000003689 pubic bone Anatomy 0.000 description 1
210000001747 pupil Anatomy 0.000 description 1
239000008213 purified water Substances 0.000 description 1
WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 1
230000001698 pyrogenic effect Effects 0.000 description 1
239000002516 radical scavenger Substances 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
239000012857 radioactive material Substances 0.000 description 1
239000000941 radioactive substance Substances 0.000 description 1
238000002601 radiography Methods 0.000 description 1
239000012217 radiopharmaceutical Substances 0.000 description 1
229940121896 radiopharmaceutical Drugs 0.000 description 1
230000002799 radiopharmaceutical effect Effects 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
206010037833 rales Diseases 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
230000008707 rearrangement Effects 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
238000000611 regression analysis Methods 0.000 description 1
230000008263 repair mechanism Effects 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000011347 resin Substances 0.000 description 1
XWGJFPHUCFXLBL-UHFFFAOYSA-M rongalite Chemical compound [Na+].OCS([O-])=O XWGJFPHUCFXLBL-UHFFFAOYSA-M 0.000 description 1
101150042287 ros gene Proteins 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000013391 scatchard analysis Methods 0.000 description 1
239000006152 selective media Substances 0.000 description 1
230000028043 self proteolysis Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
230000035939 shock Effects 0.000 description 1
231100000161 signs of toxicity Toxicity 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
238000001542 size-exclusion chromatography Methods 0.000 description 1
210000002356 skeleton Anatomy 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
210000004872 soft tissue Anatomy 0.000 description 1
239000007787 solid Substances 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000012086 standard solution Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000008227 sterile water for injection Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
229910052682 stishovite Inorganic materials 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
210000005127 stratified epithelium Anatomy 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
239000012134 supernatant fraction Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
230000008685 targeting Effects 0.000 description 1
238000004448 titration Methods 0.000 description 1
230000001256 tonic effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000041 toxicology testing Toxicity 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
JREYOWJEWZVAOR-UHFFFAOYSA-N triazanium;[3-methylbut-3-enoxy(oxido)phosphoryl] phosphate Chemical compound [NH4+].[NH4+].[NH4+].CC(=C)CCOP([O-])(=O)OP([O-])([O-])=O JREYOWJEWZVAOR-UHFFFAOYSA-N 0.000 description 1
229910052905 tridymite Inorganic materials 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
238000010200 validation analysis Methods 0.000 description 1
ACWBQPMHZXGDFX-QFIPXVFZSA-N valsartan Chemical class C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=NN1 ACWBQPMHZXGDFX-QFIPXVFZSA-N 0.000 description 1
229910052720 vanadium Inorganic materials 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
238000009941 weaving Methods 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
201000009482 yaws Diseases 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/534—Production of labelled immunochemicals with radioactive label
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Urology & Nephrology (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pathology (AREA)
Food Science & Technology (AREA)
General Physics & Mathematics (AREA)
Biochemistry (AREA)
Analytical Chemistry (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Investigating Or Analysing Biological Materials (AREA)
Steroid Compounds (AREA)
Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Packages (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

UA2001096636A 1999-03-01 2000-02-29 Method of radioactive marking of cd 20 antibody UA78484C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/259,337 US20020102208A1 (en)	1999-03-01	1999-03-01	Radiolabeling kit and binding assay
PCT/US2000/005061 WO2000052473A2 (en)	1999-03-01	2000-02-29	Radiolabeling kit and binding assay

Publications (1)

Publication Number	Publication Date
UA78484C2 true UA78484C2 (en)	2007-04-10

Family

ID=22984524

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2001096636A UA78484C2 (en)	1999-03-01	2000-02-29	Method of radioactive marking of cd 20 antibody

Country Status (35)

Country	Link
US (2)	US20020102208A1 (de)
EP (2)	EP2112512B1 (de)
JP (1)	JP4704570B2 (de)
KR (1)	KR100729247B1 (de)
CN (1)	CN1235639C (de)
AT (1)	ATE433108T1 (de)
AU (1)	AU776747B2 (de)
BG (1)	BG65690B1 (de)
BR (2)	BRPI0017596B8 (de)
CA (2)	CA2362119C (de)
CY (2)	CY1109335T1 (de)
CZ (2)	CZ303262B6 (de)
DE (1)	DE60042326D1 (de)
DK (2)	DK2112512T3 (de)
EE (1)	EE05650B1 (de)
ES (2)	ES2328100T3 (de)
HK (1)	HK1045730B (de)
HR (1)	HRP20010714B1 (de)
HU (2)	HU229627B1 (de)
IL (1)	IL145109A0 (de)
ME (1)	ME00782B (de)
MX (1)	MXPA01008837A (de)
MY (1)	MY138674A (de)
NO (2)	NO329142B1 (de)
NZ (2)	NZ513788A (de)
PL (1)	PL205780B1 (de)
PT (2)	PT1192463E (de)
RS (1)	RS51778B (de)
RU (1)	RU2251110C2 (de)
SI (2)	SI2112512T1 (de)
SK (2)	SK287745B6 (de)
TW (1)	TWI294969B (de)
UA (1)	UA78484C2 (de)
WO (1)	WO2000052473A2 (de)
ZA (1)	ZA200106943B (de)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6136311A (en)	1996-05-06	2000-10-24	Cornell Research Foundation, Inc.	Treatment and diagnosis of cancer
US6107090A (en)	1996-05-06	2000-08-22	Cornell Research Foundation, Inc.	Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
US20020102208A1 (en) *	1999-03-01	2002-08-01	Paul Chinn	Radiolabeling kit and binding assay
MY133346A (en)	1999-03-01	2007-11-30	Biogen Inc	Kit for radiolabeling ligands with yttrium-90
US6207858B1 (en) *	1999-03-03	2001-03-27	Idec Pharmaceuticals Corporation	Regioselective synthesis of DTPA derivatives
EP1918305A1 (de)	1999-08-11	2008-05-07	Biogen Idec Inc.	Neue klinische Parameter zur Bestimmung der hämatologischen Toxizität vor einer Strahlenimmuntherapie
JP4202127B2 (ja)	2000-10-02	2008-12-24	ノバルティスバクシンズアンドダイアグノスティックス，インコーポレーテッド	アンタゴニスト抗ｃｄ４０抗体を用いるｂ細胞悪性腫瘍の治療方法
US20030003097A1 (en) *	2001-04-02	2003-01-02	Idec Pharmaceutical Corporation	Recombinant antibodies coexpressed with GnTIII
US7514078B2 (en)	2001-06-01	2009-04-07	Cornell Research Foundation, Inc.	Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
EP2277542B1 (de)	2001-06-01	2014-04-16	Cornell Research Foundation Inc.	Modifizierte Antikörper gegen prostata-spezifisches Membranantigen und ihre Verwendungen
IL159422A0 (en)	2001-09-20	2004-06-01	Cornell Res Foundation Inc	Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate-specific membrane antigen
ATE408712T1 (de)	2003-01-10	2008-10-15	Millennium Pharm Inc	Verfahren zur bestimmung des wiederauftretens von prostata krebs
TWI353991B (en)	2003-05-06	2011-12-11	Syntonix Pharmaceuticals Inc	Immunoglobulin chimeric monomer-dimer hybrids
NZ543495A (en) *	2003-06-25	2009-04-30	Peregrine Pharmaceuticals Inc	Method and apparatus for continuous large-scale radiolabeling of proteins
ATE474598T1 (de)	2003-11-04	2010-08-15	Novartis Vaccines & Diagnostic	Verwendung von antagonisten-anti-cd40-antikörpern zur behandlung von chronisch lymphozytischer leukämie
CA2544951A1 (en)	2003-11-04	2005-05-19	Chiron Corporation	Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
PT1694360E (pt)	2003-11-04	2010-12-13	Novartis Vaccines & Diagnostic	Utilização de anticorpos monoclonais antagonistas anti-cd40 para o tratamento de doenças auto-imunes e inflamatórias e da rejeição ao transplante de orgãos
EP1680141B8 (de)	2003-11-04	2011-01-12	Novartis Vaccines and Diagnostics, Inc.	Verfahren zur behandlung von soliden tumoren mit expression des cd40-zelloberflächen-antigens
EP1844815B1 (de)	2003-11-04	2011-09-14	Novartis Vaccines and Diagnostics, Inc.	Kombinationstherapie von anti-CD20 und anti-CD40 Antikörpern zur Behandlung von B-Zell-bedingtem Krebs
WO2006125117A2 (en)	2005-05-18	2006-11-23	Novartis Ag	Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
SI1904104T1 (sl)	2005-07-08	2013-12-31	Biogen Idec Ma Inc.	Protitelesa SP35 in njihova uporaba
JP5123183B2 (ja) *	2005-08-25	2013-01-16	コーニンクレッカフィリップスエレクトロニクスエヌヴィ	標的療法のための画像ベースの計画方法及び装置
DK2963011T3 (en)	2005-11-23	2018-08-06	Ventana Med Syst Inc	MOLECULAR CONJUGATE
MX2008013508A (es)	2006-04-21	2008-10-31	Novartis Ag	Composiciones farmaceuticas de anticuerpos antagonistas anti-cd40.
EP2037967B1 (de)	2006-06-16	2016-12-07	The Trustees Of The University Of Pennsylvania	Prostaglandin d2 rezeptor antagonisten zur behandlung androgener alopezie
US9382327B2 (en) *	2006-10-10	2016-07-05	Vaccinex, Inc.	Anti-CD20 antibodies and methods of use
RU2448973C2 (ru) *	2006-11-10	2012-04-27	Альфаптозе ГмбХ	Применение соединений три-замещенного глицерина для лечения радиационных поражений
CZ300074B6 (cs) *	2006-12-20	2009-01-21	Azacycles S. R. O.	Inteligentní trífunkcní makrokonjugáty a farmaceutický nebo diagnostický prostredek s jejich obsahem
GB0700133D0 (en)	2007-01-04	2007-02-14	Humabs Llc	Human cytomegalovirus neutralising antibodies and use thereof
CN101636168B (zh)	2007-01-09	2013-05-29	比奥根艾迪克Ma公司	Sp35抗体及其用途
KR101247418B1 (ko) *	2007-12-21	2013-03-25	에프. 호프만-라 로슈 아게	항체 제형
DK2982695T3 (da)	2008-07-09	2019-05-13	Biogen Ma Inc	Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf
PE20141435A1 (es)	2008-07-16	2014-10-22	Inst Research In Biomedicine	Anticuerpos neutralizantes de citomegalovirus humano
EP2303923B1 (de)	2008-07-16	2015-06-24	Institute for Research in Biomedicine	Das humane cytomegalovirus neutralisierende antikörper und anwendung davon
US8871207B2 (en)	2008-07-25	2014-10-28	Humabs, LLC	Neutralizing anti-influenza A virus antibodies and uses thereof
WO2010010467A2 (en)	2008-07-25	2010-01-28	Institute For Research In Biomedicine	Neutralizing anti-influenza a virus antibodies and uses thereof
MX2011003588A (es)	2008-10-13	2011-10-14	Inst Research In Biomedicine	Anticuerpos neutralizadores del virus del dengue y uso de los mismos.
JP2012514458A (ja)	2008-12-31	2012-06-28	バイオジェン・アイデック・エムエイ・インコーポレイテッド	抗リンホトキシン抗体
WO2011092593A2 (en)	2010-01-20	2011-08-04	Institute For Research In Biomedicine	Hiv-1 neutralizing antibodies and uses thereof
ME02464B (de)	2010-03-12	2017-02-20	Genzyme Corp	Kombinationstherapie zur Behandlung von Brustkrebs
SG10201505217WA (en)	2010-07-09	2015-08-28	Biogen Hemophilia Inc	Chimeric clotting factors
PL2601214T3 (pl)	2010-08-06	2018-05-30	Genzyme Corporation	Kompozycje antagonistyczne wobec VEGF oraz ich zastosowania
AU2011288946A1 (en) *	2010-08-13	2013-03-21	Rdm Empreendimentos E Participacoes S.A.	Method and composition for reducing the color of sugar
AU2012229336B2 (en)	2011-03-11	2017-02-02	Genzyme Corporation	Pegylated Apelin and uses thereof
HRP20190714T1 (hr)	2011-07-18	2019-06-14	Institute For Research In Biomedicine	Neutralizirajuća protutijela anti-influenca a virusa i njihova uporaba
UY34317A (es)	2011-09-12	2013-02-28	Genzyme Corp	Anticuerpo antireceptor de célula T (alfa)/ß
US9764038B2 (en)	2011-12-23	2017-09-19	Innate Pharma	Enzymatic conjugation of antibodies
NZ630920A (en)	2012-03-20	2017-01-27	Humabs Biomed Sa	Antibodies that neutralize rsv, mpv and pvm and uses thereof
RS57413B1 (sr)	2012-03-28	2018-09-28	Sanofi Sa	Antitela za ligande bradikinin b1 receptora
WO2013175276A1 (en)	2012-05-23	2013-11-28	Argen-X B.V	Il-6 binding molecules
RU2522203C2 (ru) *	2012-06-26	2014-07-10	Василий Александрович Ишутин	Способ контроля стерилизации материалов и изделий
WO2014009426A2 (en) *	2012-07-13	2014-01-16	Innate Pharma	Screening of conjugated antibodies
US9790268B2 (en)	2012-09-12	2017-10-17	Genzyme Corporation	Fc containing polypeptides with altered glycosylation and reduced effector function
US10036010B2 (en)	2012-11-09	2018-07-31	Innate Pharma	Recognition tags for TGase-mediated conjugation
CN110256560A (zh)	2013-03-11	2019-09-20	建新公司	通过糖工程的位点特异性抗体-药物偶联
WO2014165216A1 (en)	2013-03-12	2014-10-09	The Trustees Of The University Of Pennsylvania	Diagnosing and treating cancer
EP2968582B1 (de)	2013-03-15	2020-07-01	Innate Pharma	Festphasen-tgase-vermittelte konjugation von antikörpern
EP3010547B1 (de)	2013-06-20	2021-04-21	Innate Pharma	Enzymatische konjugation von polypeptiden
JP6744212B2 (ja)	2013-06-21	2020-08-19	イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅＰｈａｒｍａＰｈａｒｍａＳ．Ａ．	ポリペプチドの酵素的結合
RU2558929C2 (ru) *	2013-08-08	2015-08-10	Федеральное государственное бюджетное учреждение "Научно-исследовательский институт кардиологии" (НИИ Кардиологии)	СПОСОБ ОПРЕДЕЛЕНИЯ СВЯЗЫВАНИЯ РАДИОФАРМПРЕПАРАТА НА ОСНОВЕ ЦИПРОФЛОКСАЦИНА, МЕЧЕННОГО 99mTc C БАКТЕРИЯМИ
TN2016000048A1 (en)	2013-08-13	2017-07-05	Sanofi Sa	Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof
US11052177B2 (en)	2013-09-06	2021-07-06	The Trustees Of The University Of Pennsylvania	Antimicrobial polymer layers
EP3733244A1 (de)	2013-10-02	2020-11-04	Medlmmune, LLC	Neutralisierende antiinflueanza-a-virus-antikörper und verwendungen davon
NZ723336A (en)	2014-02-27	2017-04-28	Univ Texas	Methods and compositions for isolating exosomes
PL3129067T3 (pl)	2014-03-19	2023-05-08	Genzyme Corporation	Specyficzne dla miejsca glikomodyfikowanie ugrupowań celujących
MA39708A (fr)	2014-03-27	2021-03-31	Bird Rock Bio Inc	Anticorps qui se lient au récepteur cannabinoïde 1 (cb1) humain
CN119161468A (zh)	2014-07-15	2024-12-20	免疫医疗有限责任公司	中和抗乙型流感抗体及其用途
WO2016014613A1 (en)	2014-07-22	2016-01-28	The Trustees Of The University Of Pennsylvania	Compositions and methods for cancer immunotherapy
WO2016055950A1 (en)	2014-10-08	2016-04-14	Novartis Ag	Combination of human cytomegalovirus neutralizing antibodies
PT3204425T (pt)	2014-10-09	2020-12-18	Genzyme Corp	Conjugados anticorpo fármaco glicomanipulados
WO2016075546A2 (en)	2014-11-14	2016-05-19	Antonio Lanzavecchia	Antibodies that neutralize ebola virus and uses thereof
BR122020023406B1 (pt)	2014-11-18	2023-10-31	Institut Pasteur	Anticorpos que neutralizam de modo potente vírus da raiva e outros lissavírus, moléculas de ácido nucleico, vetor, célula isolada, composição farmacêutica, usos dos mesmos, e kit de partes
CN113480640B (zh)	2015-06-01	2024-07-30	免疫医疗有限责任公司	中和抗流感结合分子及其用途
ES2947824T3 (es)	2015-07-30	2023-08-21	Univ Pennsylvania	Alelos polimórficos de un solo nucleótido del gen DP-2 humano para la detección de la susceptibilidad a la inhibición del crecimiento del cabello por antagonistas de PGD2
US10278438B2 (en)	2015-08-31	2019-05-07	Grabbies Media, Llc	Consumer usable device with redeemable member
US10633445B2 (en)	2015-09-15	2020-04-28	Board Of Regents The University Of Texas System	T-cell receptor (TCR)-binding antibodies and uses thereof
BR112018006633A2 (en)	2015-09-30	2018-10-23	Bird Rock Bio, Inc.	antibodies that bind to human cannabinoid receptor 1 (cb1)
WO2017059878A1 (en)	2015-10-07	2017-04-13	Humabs Biomed Sa	Antibodies that potently neutralize hepatitis b virus and uses thereof
WO2017123685A1 (en)	2016-01-13	2017-07-20	Medimmune, Llc	Method of treating influenza a
WO2018010789A1 (en)	2016-07-13	2018-01-18	Humabs Biomed Sa	Novel antibodies specifically binding to zika virus epitopes and uses thereof
UA129243C2 (uk)	2017-04-19	2025-02-26	Інстітьют Фо Рісьорч Ін Біомедцін	Антитіло, що зв'язується зі спорозоїтами p. falciparum
WO2018204895A1 (en)	2017-05-05	2018-11-08	Vaccinex, Inc.	Human anti-semaphorin 4d antibody
BR112020001074A2 (pt)	2017-07-19	2020-07-14	Hoffman Technologies, Inc.	composição
WO2019042555A1 (en)	2017-08-31	2019-03-07	Humabs Biomed Sa	MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF
CN109550061A (zh) *	2017-09-26	2019-04-02	南京江原安迪科正电子研究发展有限公司	一种用于放射性核素标记抗体的试剂盒及应用
RU2700584C1 (ru) *	2018-12-13	2019-09-18	Общество С Ограниченной Ответственностью "Апто-Фарм"	Способ оценки сродства олигонуклеотида
MX2021006756A (es)	2018-12-19	2021-09-28	Humabs Biomed Sa	Anticuerpos que neutralizan el virus de la hepatitis b y usos de los mismos.
MA55529A (fr)	2019-04-03	2022-02-09	Genzyme Corp	Polypeptides de liaison anti-alpha bêta tcr à fragmentation réduite
KR20220063188A (ko)	2019-08-29	2022-05-17	비르 바이오테크놀로지, 인코포레이티드	B형 간염 바이러스 감염을 치료하기 위한 항체 조성물 및 방법
EP4110404A1 (de)	2020-02-28	2023-01-04	Genzyme Corporation	Modifizierte bindende polypeptide zur optimierten wirkstoffkonjugation
JP7748728B2 (ja)	2020-06-11	2025-10-03	インペリアル・カレッジ・イノベーションズ・リミテッド	末梢神経再生を促進するためのｃｘｃｌ１３結合分子の使用
JP2024504167A (ja)	2021-01-26	2024-01-30	ヴィア・バイオテクノロジー・インコーポレイテッド	Ｂ型肝炎ウイルス感染を処置するための抗体組成物および方法
TW202430561A (zh)	2022-09-30	2024-08-01	法商賽諾菲公司	抗cd28抗體
KR20250094703A (ko)	2022-10-25	2025-06-25	아블린쓰 엔.브이.	향상된 효과기 기능을 갖는 당조작된 Fc 변이체 폴리펩타이드
US12195546B2 (en)	2022-12-19	2025-01-14	Sanofi	CD28/OX40 bispecific antibodies
WO2025177185A1 (en) *	2024-02-20	2025-08-28	Janssen Biotech, Inc.	Materials and methods for biologic affinity analysis
WO2025257408A1 (en)	2024-06-14	2025-12-18	Sanofi	Treatment of solid organ transplant subjects with cd28/ox40 bispecific antibodies
WO2026024319A1 (en)	2024-07-23	2026-01-29	Bird Rock Bio Sub, Inc.	Treatment of obesity and obstructive sleep apnea

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3994966A (en) *	1972-09-28	1976-11-30	The Board Of Trustees Of The Leland Stanford Junior University	Chelating agents
US4043998A (en) *	1974-10-09	1977-08-23	The Board Of Trustees Of The Leland Stanford Junior University	1-(P-benzenediazonium)-ethylenediamine tetraacetic acid
US4315851A (en) *	1978-12-29	1982-02-16	Kureha Kagaku Kogyo Kabushiki Kaisha	Pharmaceutical composition having antitumor activity
US4348376A (en) *	1980-03-03	1982-09-07	Goldenberg Milton David	Tumor localization and therapy with labeled anti-CEA antibody
US4331647A (en) *	1980-03-03	1982-05-25	Goldenberg Milton David	Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4460559A (en) *	1980-03-03	1984-07-17	Goldenberg Milton David	Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4361544A (en) *	1980-03-03	1982-11-30	Goldenberg Milton David	Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4444744A (en) *	1980-03-03	1984-04-24	Goldenberg Milton David	Tumor localization and therapy with labeled antibodies to cell surface antigens
US4460561A (en) *	1980-03-03	1984-07-17	Goldenberg M David	Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4622420A (en) *	1980-03-18	1986-11-11	The Regents Of The University Of California	Chelating agents and method
US4454106A (en) *	1982-06-07	1984-06-12	Gansow Otto A	Use of metal chelate conjugated monoclonal antibodies
US4472509A (en) *	1982-06-07	1984-09-18	Gansow Otto A	Metal chelate conjugated monoclonal antibodies
JPS5982222U (ja) *	1982-11-26	1984-06-02	松井　三郎	眼鏡
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4707352A (en) *	1984-01-30	1987-11-17	Enzo Biochem, Inc.	Method of radioactively labeling diagnostic and therapeutic agents containing a chelating group
US4636380A (en)	1984-04-23	1987-01-13	Wong Dennis W	Novel physiologic chemical method of labeling protein substances with the radionuclides of indium
US4634586A (en) *	1984-05-21	1987-01-06	The Board Of Trustees Of The Leland Stanford Junior University	Reagent and method for radioimaging leukocytes
US4722892A (en) *	1984-08-31	1988-02-02	Meares Claude F	Monoclonal antibodies against metal chelates
US4824986A (en) *	1985-04-26	1989-04-25	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Metal chelate protein conjugate
US5101827A (en) *	1985-07-05	1992-04-07	Immunomedics, Inc.	Lymphographic and organ imaging method and kit
US4735210A (en) *	1985-07-05	1988-04-05	Immunomedics, Inc.	Lymphographic and organ imaging method and kit
US4926869A (en) *	1986-01-16	1990-05-22	The General Hospital Corporation	Method for the diagnosis and treatment of inflammation
CA1266344A (en) *	1986-02-14	1990-02-27	Miki Kurami	High molecular compounds having amino groups, and their utilization
US5099069A (en)	1986-09-05	1992-03-24	Gansow Otto A	Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5246692A (en) *	1986-09-05	1993-09-21	The United States Of America As Represented By The Secretary Of Health And Human Services	Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US4831175A (en) *	1986-09-05	1989-05-16	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
EP0484989B1 (de) *	1986-09-05	1996-04-24	GANSOW, Otto A.	Polysubstituierte Diethylentriamin Chelate zur Bildung einer Metall-Chelat-Protein Konjugierung
US5034223A (en) *	1986-10-09	1991-07-23	Neorx Corporation	Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
US4921690A (en) *	1986-12-29	1990-05-01	City Of Hope	Method of enhancing the biodistribution of antibody for localization in lesions
IL85035A0 (en) *	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU619218B2 (en)	1987-11-06	1992-01-23	Abbott Laboratories	Methods and materials for the preparation of metal labelled antibody solutions
US5130118A (en)	1987-11-06	1992-07-14	Abbott Laboratories	Methods and materials for the preparation of metal labelled antibody solutions
US5217704A (en)	1987-11-06	1993-06-08	Abbott Laboratories	Methods and materials for the preparation of metal labelled antibody solutions
US4978745A (en)	1987-11-23	1990-12-18	Centocor, Inc.	Immunoreactive heterochain antibodies
US4861579A (en) *	1988-03-17	1989-08-29	American Cyanamid Company	Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies
US4975369A (en)	1988-04-21	1990-12-04	Eli Lilly And Company	Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
AU630362B2 (en) *	1988-05-25	1992-10-29	United States of America, as represented by the Secretary, U.S. Department of Commerce, The	Macrocyclic chelates & methods of use thereof
US4923985A (en) *	1988-05-25	1990-05-08	The United States Of America As Represented By The Department Of Health & Human Services	Process for synthesizing macrocyclic chelates
US5059518A (en) *	1988-10-20	1991-10-22	Coulter Corporation	Stabilized lyophilized mammalian cells and method of making same
CA2010511A1 (en)	1989-03-01	1990-09-01	Roberto L. Ceriani	Method of enhancing cancer therapy by administration of unsaturated fatty acids
US5376356A (en) *	1989-03-14	1994-12-27	Neorx Corporation	Imaging tissue sites of inflammation
US5162115A (en) *	1989-05-09	1992-11-10	Pietronigro Dennis D	Antineoplastic solution and method for treating neoplasms
US5460785A (en)	1989-08-09	1995-10-24	Rhomed Incorporated	Direct labeling of antibodies and other protein with metal ions
US5124471A (en) *	1990-03-26	1992-06-23	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Bifunctional dtpa-type ligand
US5219556A (en) *	1990-07-09	1993-06-15	Mallinckrodt Medical, Inc.	Stabilized therapeutic radiopharmaceutical complexes
US5009069A (en) *	1990-08-24	1991-04-23	Molini Alberto E	Method of recovering energy from ocean water
GB9022543D0 (en) *	1990-10-17	1990-11-28	Wellcome Found	Antibody production
JPH06501705A (ja)	1990-11-05	1994-02-24	ブリストル−マイアーズ　スクイブ　カンパニー	抗−腫瘍抗体及び生物学的活性剤の組合せによる相乗治療
US5208008A (en) *	1990-11-14	1993-05-04	University Of Pittsburgh	Regioselective chemical modification of monoclonal antibodies
IL100626A0 (en) *	1991-01-11	1992-09-06	Cryopharm Corp	A method of forming dry cells,diagnostic panels containing the same and diagnostic methods utilizing the same
US5403573A (en) *	1992-04-23	1995-04-04	The Curators Of The University Of Missouri	Radiolabeled protein composition and method for radiation synovectomy
US5541287A (en)	1992-06-09	1996-07-30	Neorx Corporation	Pretargeting methods and compounds
US5716596A (en)	1992-06-23	1998-02-10	Diatide, Inc.	Radioactively labeled somatostatin-derived peptides for imaging and therapeutic uses
US5620675A (en)	1992-06-23	1997-04-15	Diatech, Inc.	Radioactive peptides
MD1367C2 (ro) *	1992-11-13	2000-11-30	Idec Pharmaceuticals Corporation	Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
US5736137A (en)	1992-11-13	1998-04-07	Idec Pharmaceuticals Corporation	Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5650134A (en)	1993-01-12	1997-07-22	Novartis Ag (Formerly Sandoz Ltd.)	Peptides
US5595721A (en) *	1993-09-16	1997-01-21	Coulter Pharmaceutical, Inc.	Radioimmunotherapy of lymphoma using anti-CD20
IL113610A0 (en) *	1994-06-03	1995-08-31	Immunomedics Inc	A method of radiolabeling a protein, radiolabeled proteins prepared thereby and diagnostic kits containing the same
US5686578A (en)	1994-08-05	1997-11-11	Immunomedics, Inc.	Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
US5874540A (en)	1994-10-05	1999-02-23	Immunomedics, Inc.	CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
US5728369A (en) *	1994-10-05	1998-03-17	Immunomedics, Inc.	Radioactive phosphorus labeling of proteins for targeted radiotherapy
US5942210A (en)	1994-11-15	1999-08-24	Cytogen Corporation	Methods for lyoprotecting a macromolecule using tricine
US5830431A (en)	1995-06-07	1998-11-03	Mallinckrodt Medical, Inc.	Radiolabeled peptide compositions for site-specific targeting
US5961955A (en) *	1997-06-03	1999-10-05	Coulter Pharmaceutical, Inc.	Radioprotectant for peptides labeled with radioisotope
US20020102208A1 (en) *	1999-03-01	2002-08-01	Paul Chinn	Radiolabeling kit and binding assay
MY133346A (en) *	1999-03-01	2007-11-30	Biogen Inc	Kit for radiolabeling ligands with yttrium-90

1999
- 1999-03-01 US US09/259,337 patent/US20020102208A1/en not_active Abandoned
2000
- 2000-02-28 MY MYPI20000754A patent/MY138674A/en unknown
- 2000-02-29 SI SI200031085T patent/SI2112512T1/sl unknown
- 2000-02-29 CZ CZ20013126A patent/CZ303262B6/cs not_active IP Right Cessation
- 2000-02-29 SK SK1216-2001A patent/SK287745B6/sk not_active IP Right Cessation
- 2000-02-29 AU AU35052/00A patent/AU776747B2/en not_active Expired
- 2000-02-29 SI SI200031036T patent/SI1192463T1/sl unknown
- 2000-02-29 BR BRPI0017596A patent/BRPI0017596B8/pt not_active IP Right Cessation
- 2000-02-29 RS YU61601A patent/RS51778B/sr unknown
- 2000-02-29 NZ NZ513788A patent/NZ513788A/xx not_active IP Right Cessation
- 2000-02-29 EP EP09158514.1A patent/EP2112512B1/de not_active Expired - Lifetime
- 2000-02-29 JP JP2000602634A patent/JP4704570B2/ja not_active Expired - Lifetime
- 2000-02-29 IL IL14510900A patent/IL145109A0/xx not_active IP Right Cessation
- 2000-02-29 UA UA2001096636A patent/UA78484C2/uk unknown
- 2000-02-29 BR BRPI0008719-0 patent/BRPI0008719B8/pt not_active IP Right Cessation
- 2000-02-29 DK DK09158514.1T patent/DK2112512T3/en active
- 2000-02-29 DK DK00913645T patent/DK1192463T3/da active
- 2000-02-29 EP EP00913645A patent/EP1192463B1/de not_active Expired - Lifetime
- 2000-02-29 EE EEP200100465A patent/EE05650B1/xx unknown
- 2000-02-29 HK HK02107258.0A patent/HK1045730B/zh not_active IP Right Cessation
- 2000-02-29 PL PL352531A patent/PL205780B1/pl unknown
- 2000-02-29 HU HU0202522A patent/HU229627B1/hu unknown
- 2000-02-29 ME MEP-2009-21A patent/ME00782B/me unknown
- 2000-02-29 NZ NZ530868A patent/NZ530868A/en not_active IP Right Cessation
- 2000-02-29 MX MXPA01008837A patent/MXPA01008837A/es active IP Right Grant
- 2000-02-29 AT AT00913645T patent/ATE433108T1/de active
- 2000-02-29 HR HR20010714A patent/HRP20010714B1/xx not_active IP Right Cessation
- 2000-02-29 KR KR1020017011093A patent/KR100729247B1/ko not_active Expired - Lifetime
- 2000-02-29 CZ CZ2010-746A patent/CZ306959B6/cs not_active IP Right Cessation
- 2000-02-29 CA CA2362119A patent/CA2362119C/en not_active Expired - Lifetime
- 2000-02-29 ES ES00913645T patent/ES2328100T3/es not_active Expired - Lifetime
- 2000-02-29 SK SK91-2010A patent/SK288096B6/sk not_active IP Right Cessation
- 2000-02-29 HU HU1300275A patent/HU230516B1/hu unknown
- 2000-02-29 WO PCT/US2000/005061 patent/WO2000052473A2/en not_active Ceased
- 2000-02-29 CN CNB008057397A patent/CN1235639C/zh not_active Expired - Lifetime
- 2000-02-29 PT PT00913645T patent/PT1192463E/pt unknown
- 2000-02-29 PT PT91585141T patent/PT2112512E/pt unknown
- 2000-02-29 RU RU2001126400/15A patent/RU2251110C2/ru active
- 2000-02-29 DE DE60042326T patent/DE60042326D1/de not_active Expired - Lifetime
- 2000-02-29 ES ES09158514.1T patent/ES2526723T3/es not_active Expired - Lifetime
- 2000-02-29 CA CA2742153A patent/CA2742153C/en not_active Expired - Lifetime
- 2000-03-01 TW TW089103582A patent/TWI294969B/zh not_active IP Right Cessation
2001
- 2001-08-22 ZA ZA200106943A patent/ZA200106943B/xx unknown
- 2001-08-31 NO NO20014245A patent/NO329142B1/no not_active IP Right Cessation
- 2001-09-27 BG BG105957A patent/BG65690B1/bg unknown
2005
- 2005-01-12 US US11/033,439 patent/US7608241B2/en not_active Expired - Fee Related
2009
- 2009-09-01 CY CY20091100912T patent/CY1109335T1/el unknown
2010
- 2010-05-18 NO NO20100717A patent/NO330705B1/no not_active IP Right Cessation
2015
- 2015-02-16 CY CY20151100160T patent/CY1116265T1/el unknown

Also Published As

Publication number	Publication date
NO20014245D0 (no)	2001-08-31
HUP0202522A2 (hu)	2002-11-28
CN1345417A (zh)	2002-04-17
MXPA01008837A (es)	2002-05-14
SK288096B6 (sk)	2013-07-02
BRPI0008719A (pt)	2001-12-26
DK1192463T3 (da)	2009-10-05
AU776747B2 (en)	2004-09-23
NO20100717L (no)	2001-10-31
MY138674A (en)	2009-07-31
CA2362119C (en)	2012-12-11
EP2112512A3 (de)	2009-12-16
BG105957A (en)	2002-08-30
BRPI0008719B8 (pt)	2021-07-06
SK12162001A3 (sk)	2002-12-03
HK1045730B (zh)	2006-08-18
JP2002538179A (ja)	2002-11-12
IL145109A0 (en)	2002-06-30
EP2112512B1 (de)	2014-11-19
BRPI0017596B1 (pt)	2015-09-01
HUP1300275A2 (en)	2002-11-28
SI1192463T1 (sl)	2009-10-31
NO20014245L (no)	2001-10-31
ES2526723T3 (es)	2015-01-14
CY1109335T1 (el)	2014-07-02
HRP20010714A2 (en)	2003-02-28
BRPI0017596A2 (pt)	2011-09-27
HRP20010714B1 (hr)	2009-01-31
KR100729247B1 (ko)	2007-06-15
US20020102208A1 (en)	2002-08-01
EP1192463B1 (de)	2009-06-03
HU230516B1 (hu)	2016-10-28
ES2328100T3 (es)	2009-11-10
PL205780B1 (pl)	2010-05-31
DE60042326D1 (de)	2009-07-16
RS51778B (sr)	2011-12-31
RU2251110C2 (ru)	2005-04-27
ZA200106943B (en)	2002-11-22
CA2742153C (en)	2015-04-14
US7608241B2 (en)	2009-10-27
HK1131208A1 (en)	2010-01-15
ATE433108T1 (de)	2009-06-15
KR20020021772A (ko)	2002-03-22
WO2000052473A3 (en)	2002-01-31
EP2112512A2 (de)	2009-10-28
WO2000052473A2 (en)	2000-09-08
BG65690B1 (bg)	2009-06-30
NO329142B1 (no)	2010-08-30
WO2000052473A9 (en)	2001-03-08
TWI294969B (de)	2008-03-21
SI2112512T1 (sl)	2015-02-27
DK2112512T3 (en)	2014-12-15
NZ513788A (en)	2004-03-26
NO330705B1 (no)	2011-06-20
CZ303262B6 (cs)	2012-07-04
HUP0202522A3 (en)	2011-03-28
CA2742153A1 (en)	2000-09-08
CZ20013126A3 (cs)	2002-07-17
ME00782B (me)	2012-03-20
NZ530868A (en)	2005-12-23
CY1116265T1 (el)	2017-02-08
EE05650B1 (et)	2013-04-15
HU229627B1 (en)	2014-03-28
SK287745B6 (sk)	2011-08-04
US20050169838A1 (en)	2005-08-04
PT2112512E (pt)	2015-01-13
PT1192463E (pt)	2009-09-10
BRPI0017596B8 (pt)	2023-04-25
YU61601A (sh)	2004-07-15
PL352531A1 (en)	2003-08-25
BRPI0008719B1 (pt)	2015-07-21
JP4704570B2 (ja)	2011-06-15
EE200100465A (et)	2002-10-15
EP1192463A2 (de)	2002-04-03
HK1045730A1 (en)	2002-12-06
CA2362119A1 (en)	2000-09-08
CZ306959B6 (cs)	2017-10-11
CN1235639C (zh)	2006-01-11
AU3505200A (en)	2000-09-21

Publication	Publication Date	Title
UA78484C2 (en)	2007-04-10	Method of radioactive marking of cd 20 antibody
Becker et al.	1996	Rapid imaging of infections with a monoclonal antibody fragment (LeukoScan).
Volpe et al.	2018	Radionuclide-fluorescence reporter gene imaging to track tumor progression in rodent tumor models
CN114391022B (zh)	2023-12-12	抗瘦素受体的抗体
US20110097272A1 (en)	2011-04-28	Method and Materials for Use in Diagnosing Viral Myocarditis
Afzelius et al.	2020	[99mTc]-labelled interleukin-8 as a diagnostic tool compared to [18F] FDG and CT in an experimental porcine osteomyelitis model
Melick et al.	1971	Assay of parathyroid hormone in disturbances of calcium metabolism
Moroz et al.	1989	Radioimmunodetection of tumors with monoclonal antiplacental ferritin antibody: preliminary results
Stannard et al.	1972	Research and Development in Progress: Biomedical and Environmental Research Program
JPS61500611A (ja)	1986-04-03	抗イデイオタイプ抗体によって誘発される、腫瘍およびウイルスに対する免疫応答
Chopra	0	64 Cu-Labeled DOTA-conjugated rituximab, a chimeric murine/human anti-CD20 monoclonal antibody [64 Cu]-DOTA-Rituximab
Kubaštová et al.	2006	Radioiodination and biodistribution of the monoclonal antibody TU-20 and its scFv fragment
HK1131208B (en)	2015-03-27	Radiolabeling kit and binding assay